Recent progress in the design of selectin inhibitors.

The selectins are a family of cell-adhesion proteins that mediate the early stages of leukocyte recruitment from the blood stream to sites of tissue damage through recognition of the carbohydrate epitope sialyl Lewis(x) (sLe(x)). Current development of small molecule based inhibitors of this process and their clinical potential to address numerous acute and chronic diseases are explored.